Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.
Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).
Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.
These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.
<<<
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More